{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T12:11:46Z","timestamp":1752667906569,"version":"3.40.4"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013913","name":"Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013913","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The prevalence and burden of atopic dermatitis (AD) are disproportionately high in people with skin of colour. Previous research has shown that the risk of xerosis and\/or dyspigmentation is heightened in this population and may be more bothersome. However, no patient-reported instruments have been developed specifically for these disease sequelae in patients with skin of colour.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To develop and perform content validation of patient-reported outcome (PRO) questionnaires to assess AD-related xerosis and dyspigmentation in patients with skin of colour.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A targeted literature review was conducted to understand and identify AD-related disease sequelae and quality-of-life impacts relevant to patients with skin of colour and any instruments used to assess AD in the target population. Two draft PRO questionnaires assessing xerosis (X-AD) and dyspigmentation (D-AD) were developed and refined following advice meetings with three clinical experts. Questionnaire content validity was explored during hybrid concept elicitation and cognitive debriefing interviews with 15 adult and adolescent patients with skin of colour who have moderate-to-severe AD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ten concept-focused articles, 3 websites, 17 labels, 1 U.S. Food and Drug Administration compendium and 1 clinical trial confirmed that xerosis and dyspigmentation are important AD-related disease sequelae. Patients with skin of colour [47% girls\/women; mean (SD) age 33.3 (21.2) years] reported that the questionnaires were relevant to their AD experience in an appropriate recall timeframe and were readily understood, and that meaningful responses were easy to select. The final X-AD consisted of one 11-point numerical rating scale (NRS) assessing xerosis severity and two items assessing the level of bother associated with xerosis appearance and feeling over the past week (0\u20134 verbal rating scale). The final D-AD consisted of two 11-point NRS items assessing dyspigmentation severity and two items assessing the level of bother associated with how dyspigmentation looked over the past week.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The X-AD\/D-AD questionnaires were well understood and effective in capturing the experiences of xerosis and dyspigmentation in the target population in an appropriate and comprehensive way. This study supports the initial development of the questionnaires in accordance with regulatory guidelines and best practices; however, psychometric validation is required to evaluate the properties of each questionnaire and develop score interpretation guidelines.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae494","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T17:41:59Z","timestamp":1736530919000},"page":"863-873","source":"Crossref","is-referenced-by-count":2,"title":["Development of novel patient-reported outcome instruments to assess atopic dermatitis-associated dyspigmentation and xerosis in patients with skin of colour"],"prefix":"10.1093","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7095-0106","authenticated-orcid":false,"given":"Christopher","family":"Hartford","sequence":"first","affiliation":[{"name":"Regeneron Pharmaceuticals Inc. , Tarrytown, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-9165","authenticated-orcid":false,"given":"Andrew","family":"Alexis","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc. , Tarrytown, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-5121","authenticated-orcid":false,"given":"Noah A","family":"Levit","sequence":"additional","affiliation":[{"name":"Dermatology Physicians of Connecticut , Fairfield, CT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2845-2634","authenticated-orcid":false,"given":"Benjamin","family":"Banderas","sequence":"additional","affiliation":[{"name":"Adelphi Values , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-0795","authenticated-orcid":false,"given":"Andrew","family":"Yaworsky","sequence":"additional","affiliation":[{"name":"Adelphi Values , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Love","sequence":"additional","affiliation":[{"name":"Adelphi Values , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9285-8164","authenticated-orcid":false,"given":"Brad","family":"Shumel","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc. , Tarrytown, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00eblle","family":"B\u00e9go-Le-Bagousse","sequence":"additional","affiliation":[{"name":"Sanofi , Gentilly ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2125-4734","authenticated-orcid":false,"given":"Diana","family":"Rofail","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc. , Tarrytown, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"2025042813571949400_ljae494-B1","first-page":"936","article-title":"The epidemiology and global burden of atopic dermatitis: a narrative review","volume":"11","author":"Hadi","year":"2021","journal-title":"Life (Basel)"},{"key":"2025042813571949400_ljae494-B2","first-page":"590","article-title":"Atopic dermatitis: diagnosis and treatment","volume":"101","author":"Frazier","year":"2020","journal-title":"Am Fam Physician"},{"key":"2025042813571949400_ljae494-B3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","article-title":"Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection","volume":"8","author":"Fishbein","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"Suppl. 1","key":"2025042813571949400_ljae494-B4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000370220","article-title":"Atopic dermatitis: global epidemiology and risk factors","volume":"66","author":"Nutten","year":"2015","journal-title":"Ann Nutr Metab"},{"key":"2025042813571949400_ljae494-B5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2025042813571949400_ljae494-B6","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMra074081","article-title":"Atopic dermatitis","volume":"358","author":"Bieber","year":"2008","journal-title":"N Engl J Med"},{"key":"2025042813571949400_ljae494-B7","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.5688\/ajpe6353","article-title":"Exploring the community pharmacist's knowledge of celiac disease","volume":"82","author":"Avena-Woods","year":"2018","journal-title":"Am J Pharm Educ"},{"key":"2025042813571949400_ljae494-B8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2017.04.019","article-title":"Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey","volume":"77","author":"Eckert","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025042813571949400_ljae494-B9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025042813571949400_ljae494-B10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","article-title":"Racial differences in atopic dermatitis","volume":"122","author":"Brunner","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025042813571949400_ljae494-B11","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2019.06.044","article-title":"Genetic ancestry does not explain increased atopic dermatitis susceptibility or worse disease control among African American subjects in 2 large US cohorts","volume":"145","author":"Abuabara","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2025042813571949400_ljae494-B12","first-page":"466","article-title":"Top dermatologic conditions in patients of color: an analysis of nationally representative data","volume":"11","author":"Davis","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"2025042813571949400_ljae494-B13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.det.2023.02.003","article-title":"Diagnosing atopic dermatitis in skin of color","volume":"41","author":"Adawi","year":"2023","journal-title":"Dermatol Clin"},{"key":"2025042813571949400_ljae494-B14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/exd.13514","article-title":"Atopic dermatitis in diverse racial and ethnic groups\u2013variations in epidemiology, genetics, clinical presentation and treatment","volume":"27","author":"Kaufman","year":"2018","journal-title":"Exp Dermatol"},{"key":"2025042813571949400_ljae494-B15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40257-017-0333-6","article-title":"Post inflammatory hyperpigmentation: epidemiology, clinical presentation, pathogenesis and treatment","volume":"19","author":"Kaufman","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2025042813571949400_ljae494-B16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.36849\/JDD.6609","article-title":"Insights in skin of color patients with atopic dermatitis and the role of skincare in improving outcomes","volume":"21","author":"Alexis","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"2025042813571949400_ljae494-B17","first-page":"S20","article-title":"Dermatological conditions in skin of color: managing atopic dermatitis","volume":"14","author":"Sangha","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"2025042813571949400_ljae494-B18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/jdv.15999","article-title":"Validation of the patient-oriented SCORing for Atopic Dermatitis tool for black skin","volume":"34","author":"Faye","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025042813571949400_ljae494-B19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000247298","article-title":"Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis","volume":"186","author":"European Task Force on Atopic Dermatitis","year":"1993","journal-title":"Dermatology"},{"key":"2025042813571949400_ljae494-B20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jid.2021.06.033","article-title":"Differences in psychometric properties of clinician- and patient-reported outcome measures for atopic dermatitis by race and skin tone: a systematic review","volume":"142","author":"Kaundinya","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2025042813571949400_ljae494-B21","first-page":"20","article-title":"Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color","volume":"3","author":"Davis","year":"2010","journal-title":"J Clin Aesthet Dermatol"},{"key":"2025042813571949400_ljae494-B22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.36849\/JDD.7087","article-title":"Skin of color representation in clinical trials: an analysis of Clinicaltrials.gov from 2008\u20132022","volume":"22","author":"Jacobs","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"2025042813571949400_ljae494-B23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/pde.12237","article-title":"Eczema and sensitization to common allergens in the United States: a multiethnic, population-based study","volume":"31","author":"Fu","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"2025042813571949400_ljae494-B24","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","article-title":"Content validity \u2013 establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2 \u2013 assessing respondent understanding","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"2025042813571949400_ljae494-B25","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Content validity \u2013 establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1 \u2013 eliciting concepts for a new PRO instrument","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"author":"U.S. Food and Drug Administration","key":"2025042813571949400_ljae494-B26","article-title":"Patient-Focused Drug Development: Methods to Identify What Is Important to Patients"},{"author":"U.S. Food and Drug Administration","key":"2025042813571949400_ljae494-B27","article-title":"Patient-focused drug development: collecting comprehensive and representative input"},{"author":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research","key":"2025042813571949400_ljae494-B28","article-title":"Patient-reported outcome measures: use in medical product development to support labeling claims"},{"key":"2025042813571949400_ljae494-B29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/DER.0000000000000486","article-title":"Conceptual model to illustrate the symptom experience and humanistic burden associated with atopic dermatitis in adults and adolescents","volume":"30","author":"Grant","year":"2019","journal-title":"Dermatitis"},{"key":"2025042813571949400_ljae494-B30"},{"key":"2025042813571949400_ljae494-B31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2015.03.198","article-title":"How many subjects are enough for symptom-focused concept elicitation studies? A retrospective analysis of saturation across twenty-six studies","volume":"18","author":"Lamoureux","year":"2015","journal-title":"Value Health"},{"key":"2025042813571949400_ljae494-B32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.sder.2011.08.007","article-title":"Role of phototherapy in patients with skin of color","volume":"30","author":"Syed","year":"2011","journal-title":"Semin Cutan Med Surg"},{"key":"2025042813571949400_ljae494-B33","first-page":"88","article-title":"Impact of weather conditions on atopic dermatitis prevalence in Abuja, Nigeria","volume":"111","author":"Ibekwe","year":"2019","journal-title":"J Natl Med Assoc"},{"key":"2025042813571949400_ljae494-B34","first-page":"30","article-title":"Pruritus in black skin: unique molecular characteristics and clinical features","volume":"113","author":"McColl","year":"2021","journal-title":"J Natl Med Assoc"},{"key":"2025042813571949400_ljae494-B35","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.12788\/j.sder.2017.009","article-title":"Practical strategies for the diagnosis and assessment of atopic dermatitis","volume":"36","author":"Eichenfield","year":"2017","journal-title":"Semin Cutan Med Surg"},{"key":"2025042813571949400_ljae494-B36","doi-asserted-by":"crossref","first-page":"776","DOI":"10.36849\/JDD.2020.4937","article-title":"Dupilumab improves atopic dermatitis and post-inflammatory hyperpigmentation in patient with skin of color","volume":"19","author":"Grayson","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"2025042813571949400_ljae494-B37","first-page":"164","article-title":"Atopic dermatitis in adolescents with skin of color","volume":"104","author":"Poladian","year":"2019","journal-title":"Cutis"},{"key":"2025042813571949400_ljae494-B38","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/1346-8138.15750","article-title":"Children with atopic eczema experiencing increased disease severity in the pollen season more often have hay fever at a young age and a dark skin type","volume":"48","author":"Bosma","year":"2021","journal-title":"J Dermatol"},{"key":"2025042813571949400_ljae494-B39","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/DER.0000000000000813","article-title":"Three-year assessment of diversity and skin of color content in dermatitis","volume":"33","author":"Wilson","year":"2022","journal-title":"Dermatitis"},{"issue":"Suppl. 2","key":"2025042813571949400_ljae494-B40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/pde.14525","article-title":"Tips for addressing common conditions affecting pediatric and adolescent patients with skin of color","volume":"38","author":"Grayson","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"2025042813571949400_ljae494-B41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/bjd.16994","article-title":"A minimally invasive tool to study immune response and skin barrier in children with atopic dermatitis","volume":"180","author":"Hulshof","year":"2019","journal-title":"Br J Dermatol"},{"author":"National Eczema Association","key":"2025042813571949400_ljae494-B42","article-title":"Eczema in skin of color: what you need to know"},{"author":"American Academy of Dermatology Association","key":"2025042813571949400_ljae494-B43","article-title":"Can you get psoriasis if you have skin of color?"},{"author":"Skin of Color Society","key":"2025042813571949400_ljae494-B44","article-title":"Eczema"},{"author":"U.S. Food and Drug Administration","key":"2025042813571949400_ljae494-B45","article-title":"Clinical outcome assessment compendium"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae494\/61410145\/ljae494.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/5\/863\/61410145\/ljae494.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/5\/863\/61410145\/ljae494.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T17:57:31Z","timestamp":1745863051000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/5\/863\/7951375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,1,10]]},"published-print":{"date-parts":[[2025,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae494","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"type":"print","value":"0007-0963"},{"type":"electronic","value":"1365-2133"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,1,10]]}}}